OCSAW — Oculis Holding AG
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953530 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -23,568,000 | -9,970,000 | 250,335,000 | 61,614,000 | 30,998,000 |
| Mar 2026 | 0 | — | -21,728,000 | -28,852,000 | 243,993,000 | 64,564,000 | 47,345,000 |
| Dec 2025 | 0 | — | -20,633,000 | -23,514,000 | 235,963,000 | 81,329,000 | 39,893,000 |
| Sep 2025 | 0 | — | -20,296,000 | -16,855,000 | 167,836,000 | 46,440,000 | 37,242,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,678,000
Investing CF
$-34,945,000
Financing CF
$106,690,000
CapEx
$-295,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-413,366,000
Inventory
—
Receivables
$1,576,000
ST Investments
$157,470,000
EBIT TTM
$-94,128,000
Pretax Income TTM
$-94,887,000
Interest Exp TTM
$759,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,672,000 | -98,957,000 | 235,963,000 | 39,893,000 | — | -66,304,000 |
| Dec 2024 | 0 | -73,204,000 | -85,777,000 | 120,353,000 | 46,970,000 | — | -48,919,000 |
| Dec 2023 | 0 | -45,851,000 | -88,802,000 | 114,353,000 | 20,625,000 | — | -55,037,000 |
| Dec 2022 | 0 | -32,376,000 | -38,698,000 | 37,060,000 | 135,051,000 | — | -25,074,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
2026-08-24 08:00 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-08-14 20:05 · Yahoo
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
2026-08-14 13:55 · Yahoo
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
2026-08-10 08:45 · Yahoo
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
2026-08-10 07:30 · Yahoo
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
2026-08-07 02:35 · Yahoo
Oculis Reports Q2 2026 Financial Results and Provides Company Update
2026-08-06 20:05 · Yahoo
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
2026-08-03 08:00 · Yahoo
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
2026-07-02 08:00 · Yahoo
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
2026-06-11 08:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.